✨ Free AI Report
BIOXYTRAN, INC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research BIOXYTRAN, INC
Company Research

BIOXYTRAN, INC: Business Overview, Financials & Competitive Analysis

BIOXYTRAN, INC scores 3/10 on the AskCyborg Cyborg Score (Weak). High-risk preclinical biotech pursuing novel oxygen therapeutics and antiviral platforms with uncertain clinical and commercial pathway. BIOXYTRAN is a micro-cap clinical-stage biotech with minimal revenue, only 3 employees, and a market cap under $10M as of late 2025. The company has multiple early-stage drug candidates but limited cash resources and.

What is BIOXYTRAN, INC's industry? BIOXYTRAN, INC (bioxytraninc.com) operates in Biotechnology. AskCyborg classifies BIOXYTRAN, INC under Biotechnology in its company registry.

BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization o...

3/ 10Weak

Cyborg Score thesis

High-risk preclinical biotech pursuing novel oxygen therapeutics and antiviral platforms with uncertain clinical and commercial...

Read the full analyst-debate transcript →
Industry Biotechnology
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest BIOXYTRAN, INC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for BIOXYTRAN, INC

AskCyborg analysts argue the bull and bear cases for BIOXYTRAN, INC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BIOXYTRAN, INC OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

BIOXYTRAN, INC Overview

Pro stress-test →

BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke.

Strategic Profile

Pro stress-test →

The company highlights a core focus on broad-spectrum antiviral therapies, with its leading antiviral drug candidate ProLectin-M described as a complex carbohydrate therapeutic and galectin antagonist that targets viral entry mechanisms. The company's lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.

Competitive Landscape

Pro stress-test →

BIOXYTRAN competes in early-stage stroke therapeutics against clinical-stage and emerging biotech firms, as well as in antiviral drug development. Direct competition is fragmented across small-cap biotech focusing on niche therapeutic areas (hypoxia, viral infections). Larger pharmaceutical companies are not directly pursuing identical galectin-antagonist antiviral or oxygen-transport stroke platforms, reducing near-term competitive pressure but also suggesting smaller addressable markets.

Industry Context

BIOXYTRAN, INC operates in Biotechnology.

Key facts

Founded: 2008 · Headquarters: Newton, Massachusetts, US · Employees: 3 · Revenue: Estimated $0–$0.5M (no meaningful commercial revenue; clinical-stage biotech) · Market cap: $8.4M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on BIOXYTRAN, INC.

  • Completed randomized clinical trial for broad-spectrum antiviral drug (October 2025) and achieved dose optimization of ProLectin-M (May 2025), signaling pipeline advancement but still in clinical stages with no marketed products generating revenue.
  • Lead compound BXT-25 targets ischemic and hemorrhagic stroke through oxygen delivery mechanism; ProLectin-M targets viral diseases as oral antiviral. Dual-platform strategy diversifies risk but requires sustained capital to reach clinical endpoints and commercialization.
+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Initiation of coverage by Independent Research equity firm
  • November 2025Commercial distribution agreement with Khoury Medical for A-SUQAR dietary supplement
  • +1 moreTrack every material event for BIOXYTRAN, INC as it happens. Explore monitoring →
Get alerted when BIOXYTRAN, INC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare BIOXYTRAN, INC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BIOXYTRAN, INC operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about BIOXYTRAN, INC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BIOXYTRAN, INC and its top competitor on Cyborg Score”
“What did BIOXYTRAN, INC do this quarter?”
“Is BIOXYTRAN, INC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does BIOXYTRAN, INC do?+
BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization o...
What is BIOXYTRAN, INC's Cyborg Score?+
BIOXYTRAN, INC has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BIOXYTRAN, INC's main competitors?+
Named competitors include Diffuse Therapeutics, Neuralstem Inc, Athersys Inc, Achaogen Inc. The full competitive landscape is in the AskCyborg report.
How can I get the full BIOXYTRAN, INC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BIOXYTRAN, INC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BIOXYTRAN, INC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual